Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
Rhea-AI Summary
Flexion Therapeutics (Nasdaq: FLXN) announced that CEO Michael Clayman, M.D., will engage in a fireside chat at the 2021 Raymond James Human Health Innovation Conference on June 21, 2021, at 3:20 p.m. ET. This virtual event will allow investors and analysts to gain insights into the company's focus on developing local therapies for musculoskeletal conditions like osteoarthritis, the most prevalent arthritis type.
For those interested in attending, the live webcast can be accessed through the Flexion Therapeutics website.
Positive
- None.
Negative
- None.
News Market Reaction – FLXN
In the trading session that priced this news, FLXN gained 6.29%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2021 Raymond James Human Health Innovation Conference. The virtual fireside chat is scheduled to begin at 3:20 p.m. ET on Monday, June 21, 2021.
To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun. Please visit flexiontherapeutics.com.
Contact:
Scott Young
Vice President, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com